Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and advanced HER2-positive solid tumours, which have driven sales to more than $3. ...

Doctors prescribe Enhertu for certain types of breast, lung, and other cancers in ... In brief, the cancers are: HER2-positive breast cancer unresectable or metastatic HER2-low breast cancer ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

According to recent studies, there is now potential that Enhertu will replace Kadcyla. The treatment of metastatic HER2-positive breast cancer once followed a stringent treatment algorithm, but now, ...

Meanwhile, AZ and Daiichi just launched the four-arm phase 3 Destiny-Gastric05 trial to test Enhertu as a first-line treatment for HER2-positive stomach cancer. The study currently bears a primary ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu ... (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

Opens in a new tab or window In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the ...

Enhertu has the potential to be the first HER2-directed treatment for patients in the EU with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer directly following endocrine therapy ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan ... Phase III trial to evaluate the ADC in HER2-positive advanced gastric cancer, and its safety profile remains consistent ...